Latham Recognized With Two Awards From LMG Life Sciences
Firm awarded for excellence and innovation in the life science legal space.
Ben Haas is Global Vice Chair of Latham & Watkins' Healthcare & Life Sciences Practice. Mr. Haas focuses his practice on regulatory, transactional, and legislative matters involving the medical device, pharmaceutical, biotechnology, tobacco, food, cosmetic, and dietary supplement industries. Mr. Haas has counseled clients on a wide variety of regulatory matters involving the US Food and Drug Administration (FDA), including, among others:
In the transactional area, Mr. Haas provides counsel on corporate compliance, mergers and acquisitions, and other corporate transactions. He regularly assists FDA-regulated device companies in initiating, managing, and completing large, international clinical trials. He has counseled clients regarding clinical trial strategy; contracting with and managing clinical research organizations, other clinical trial vendors, and clinical trial sites and investigators in the US and in dozens of overseas jurisdictions; and communicating with US and foreign regulatory authorities, as well as institutional review boards and ethics committees, both domestic and foreign. Mr. Haas has also drafted and negotiated several types of agreements for healthcare clients, including manufacturing and supply, licensing, joint development, consulting and marketing, and distribution contracts. Finally, Mr. Haas has conducted regulatory diligence for major public and private financings, mergers and other transactions in the device, pharmaceutical, biotechnology, and dietary supplement industries.
Mr. Haas counsels clients on legislative and administrative rulemaking proceedings relating to the FDA, including issues resulting from the implementation of the Family Smoking Prevention and Tobacco Control Act of 2009, the Food and Drug Administration Amendments Act of 2007, the Medical Device User Fee and Modernization Act of 2002, the Bioterrorism Act of 2002, and the Medicare Prescription Drug Improvement and Modernization Act of 2003. He has also worked with trade associations and other clients to address specific regulatory issues in matters before several federal agencies, including the Environmental Protection Agency, Federal Trade Commission, Department of Transportation, US Department of Agriculture, and Drug Enforcement Administration.
Mr. Haas also counsels clients concerning compliance and regulatory matters arising under the Consumer Product Safety Act (CPSA), as well as other statutes administered by the US Consumer Product Safety Commission (CPSC). He has assisted clients in designing and implementing product recalls within the jurisdiction of the CPSC.
Mr. Haas has been featured by leading publications for his work in the life sciences industry. He was recognized by Chambers USA (2018-2022), recommended by The Legal 500 US (2015-2016, 2019-2022), and named a Life Sciences Star by LMG Euromoney (2015-2018).
Mr. Haas also served as a member of the Latham's Global Training and Career Enhancement Committee.
Mr. Haas has authored and co-authored articles on FDA regulatory matters, including articles in the Food and Drug Law Institute's Update Magazine and the Pharmaceutical Law & Industry Report, and has been a featured speaker and lecturer on FDA regulatory and policy matters at industry-sponsored events. Some of Mr. Haas’ recent publications include:
Firm awarded for excellence and innovation in the life science legal space.